Related Experiment Video
Updated: May 29, 2025
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Innovative cyclic peptide disrupts IL-17RB-MLK4 interaction for targeted pancreatic cancer therapy
Chun-Mei Hu1, Sui-Chih Tien1, Yung-Chen Lo1
1Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan.
Abstract:
The IL-17B/IL-17RB oncogenic signaling axis promotes pancreatic cancer progression through interaction with mixed-lineage kinase 4 (MLK4). Here, we improved the effectiveness of a therapeutic peptide (TAT-IL17RB403-416, loop peptide) that disrupted IL-17RB/MLK4 interaction by converting its linear structure into a cyclic form. The modified cyclic peptide with higher uptake efficiency inhibited pancreatic cancer cell growth and metastasis, outperforming the original linear peptide both in vitro and in an orthotopic mouse model. At the molecular level, cysteine 408 in IL-17RB was important for mediating interactions with arginine 216 within MLK4 kinase domain. This interaction was fundamental to the efficacy of the cyclic peptide. Additionally, lysine 410 in IL-17RB was essential for maintaining the structural integrity of the cyclic peptide as a protein-protein disruptor These findings provide a deeper understanding of the IL-17RB-MLK4 interaction, offering insights for developing therapeutic agents targeting this pathway in pancreatic cancer.
Insights
Researchers enhanced a peptide therapy targeting the IL-17B/IL-17RB and mixed-lineage kinase 4 (MLK4) pathway in pancreatic cancer. The new cyclic peptide effectively inhibited tumor growth and metastasis, showing improved therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- The IL-17B/IL-17RB signaling pathway, interacting with mixed-lineage kinase 4 (MLK4), drives pancreatic cancer progression.
- Targeting this oncogenic axis presents a potential therapeutic strategy for pancreatic cancer.
Purpose of the Study:
- To enhance the efficacy of a peptide inhibitor targeting the IL-17RB/MLK4 interaction.
- To investigate the molecular mechanisms underlying the peptide's therapeutic effect.
Main Methods:
- Conversion of a linear peptide (TAT-IL17RB403-416) into a cyclic form to improve cellular uptake and stability.
- In vitro assays to assess pancreatic cancer cell growth and metastasis inhibition.
- In vivo studies using an orthotopic mouse model to evaluate therapeutic effectiveness.
Main Results:
- The cyclic peptide demonstrated superior inhibition of pancreatic cancer cell growth and metastasis compared to the linear peptide.
- Specific amino acid residues, cysteine 408 in IL-17RB and arginine 216 in MLK4, were identified as critical for the interaction.
- Lysine 410 in IL-17RB was crucial for the cyclic peptide's structural integrity and function.
Conclusions:
- Cyclic peptide modification significantly enhances therapeutic potential against pancreatic cancer by improving delivery and efficacy.
- Understanding the IL-17RB-MLK4 interaction at a molecular level provides a basis for developing novel pancreatic cancer therapeutics.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy